Cov qauv molecular ntawmRetatrutidesuav nrog ob qhov kev tsim kho tshiab tseem ceeb: kev qhia txog qhov tsis yog -natural amino acid thiab dual- site PEG hloov kho. Nws lub hom phiaj tseem ceeb yog kom ua tiav kev ua kom muaj txiaj ntsig ntawm peb lub receptors thiab ntev - cov nyhuv kav ntev.
Nyob rau hauv 39-amino acid sequence ntawm Retatrutide, -aminoisobutyric acid (Aib) yog muab tso rau ntawm txoj hauj lwm 2. Qhov no tsis yog-natural amino acid ho txhim khu kev ruaj ntseg ntawm -helical qauv los ntawm kev ua rau sab saw ntim, thaum tseem tiv thaiv degradation los ntawm DPP-4 enzyme. Kev sim cov ntaub ntawv qhia tau hais tias qhov kev taw qhia ntawm Aib ncua cov tshuaj ib nrab - lub neej mus rau 6 hnub, deb tshaj li ntawm ib lub hom phiaj GLP-1 agonists (xws li semaglutide, uas yuav tsum tau Fc fusion protein hloov kho kom ua tiav 7-hnub ib nrab-lub neej). Tsis tas li ntawd, hydrophobic sab saw ntawm Aib tsim ib lub network ruaj khov nrog cov amino acids uas nyob ib sab los ntawm hydrogen bonds, kom ntseeg tau tias cov tshuaj tsis yooj yim lees paub los ntawm proteases hauv cov hlab ntsha, yog li tswj nws cov haujlwm.
|
|
|
|
|
Dual PEG Modification Optimizes Pharmacokinetic Properties
Qhov tseem ceeb tshaj plaws ntawm Retatrutide tus qauv tsim molecular yog qhov txuas ntawm PEG2000 chains rau lysine (Lys) residues ntawm txoj haujlwm 17 thiab 26. Lub tswv yim no ua tiav peb lub luag haujlwm loj:
Txhim kho solubility
Lub hydrophilic xwm ntawm PEG ua rau cov tshuaj yooj yim soluble nyob rau hauv dej thiab tsis daws teeb meem, tsis txhob muaj cov kev txwv ntawm tsoos peptides uas yuav tsum tau cov organic solvents thiab txo qhov kev pheej hmoo ntawm txhaj tshuaj.
Txhim khu kev ruaj ntseg
PEG barrier txo kev sib cuag nrog proteolytic enzymes thiab inhibits qhov tsim ntawm oxidative impurities. Hauv kev ntsuas kev ruaj ntseg nrawm, Retatrutide khaws cia lub ntsiab lus siab tshaj plaws ntawm 98% tom qab 6 lub hlis ntawm kev cia ntawm 40 degree
Optimized hom phiaj
Los ntawm kev ncua lub sij hawm ncig, cov tshuaj sib xyaw ua haujlwm hauv cov ntaub so ntswg xws li hypothalamus thiab daim siab tau nce peb npaug. Cov kev tshawb fawb tsiaj pom tau hais tias kev hloov kho dual PEG nce cov tshuaj concentration hauv cerebrospinal kua los ntawm 2.5 npaug piv rau qhov tsis hloov kho, ncaj qha txhim kho qhov qab los noj mov hauv nruab nrab.
Kev siv tshuaj kho mob
Tus nqi kho mob ntawm Retatrutide yog txuas ntxiv los ntawm kev poob phaus yooj yim mus rau kev tswj hwm ntawm metabolic comorbidities. Nws Txoj Haujlwm Theem III TRIUMPH siv "kev sim pob tawb" tsim, ib txhij ntsuas cov tshuaj ua tau zoo ntawm kev rog rog -txog teeb meem, nthuav tawm nws cov ntawv thov hauv ntau thaj chaw kab mob.
Lub hauv caug Osteoarthritis
Hauv cov neeg mob rog rog nrog OA, Retatrutide txo qis kev sib koom ua ke los ntawm kev poob phaus, thaum GCGR txhawb nqa kev kho pob txha mos. Tom qab 68 lub lis piam ntawm kev kho mob nrog koob tshuaj 12mg:
Cov qhab nia mob tau txhim kho los ntawm qhov nruab nrab ntawm 76%, nrog ntau dua ib - yim feem pua ntawm cov neeg mob tau txais kev kho mob tiav;
Cov qhab nia ua haujlwm ntawm lub cev (WOMAC) tau txhim kho los ntawm 40%, txhim kho cov neeg mob cov qib ua haujlwm txhua hnub.
Obstructive pw tsaug zog Apnea
Los ntawm kev txo qis caj dab rog los ntawm kev poob phaus, Retatrutide ua rau muaj txiaj ntsig zoo hauv kev ua pa hauv OSA cov neeg mob. Kev sim tshuaj ntsuam xyuas pom tias AHI qhov ntsuas tau txo qis los ntawm qhov nruab nrab ntawm 50% hauv 12mg koob tshuaj, nrog rau 65% kev txhim kho hauv cov neeg mob hnyav (AHI Ntau dua lossis sib npaug rau 30).
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Retatrutide ho txhim kho MASLD pathological nta los ntawm kev poob phaus thiab kev tswj ncaj qha ntawm daim siab metabolism:
48 lub lis piam ntawm kev kho mob txo cov roj siab hauv siab los ntawm 80%, thiab lub siab enzyme (ALT, AST) qib txo qis los ntawm 60%;
Tus qhab nia ntawm daim siab fibrosis (FIB-4) txo qis los ntawm 40%, ua rau qeeb tus kab mob mus rau cirrhosis.
Mob plawv
Retatrutide significantly lowers non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TG), while increasing high-density lipoprotein cholesterol (HDL-C). Tom qab 68 lub lis piam ntawm kev kho mob nrog koob tshuaj 12mg:
tsis yog-HDL-C poob los ntawm 35%, TG poob los ntawm 50%, thiab HDL-C nce 20%;
Systolic ntshav siab txo los ntawm 10 mmHg, diastolic ntshav siab txo los ntawm 5 mmHg, thiab cov kev pheej hmoo ntawm cov kab mob plawv txo los ntawm 30%.
Balancing Efficacy nrog Tolerability
Common Adverse Events: Gastrointestinal Dominance
Raws li nrog rau lwm cov GLP-1R agonists, Retatrutide cov kev mob tshwm sim feem ntau yog plab hnyuv (GI), suav nrog:
Ntshai: 43.2% (12 mg koob) vs . 10.7% placebo.
ntuav: 20.9% vs . 0.0% placebo.
Mob plab: 33.1% vs . 13.4% placebo.
Cov xwm txheej no feem ntau yog mob me mus rau nruab nrab, ib ntus, thiab koob tshuaj - nyob ntawm, nrog qhov hnyav nce siab thaum lub lim tiam 12 thiab poob qis tom qab ntawd.
Cov xwm txheej tsis zoo
请替换当前 的更多内容Siv rau hauv cov tshuab conveyor xws li conveyors, nws tuaj yeem thauj khoom noj, dej haus, nplej, thiab lwm yam khoom siv los ntawm ib qho chaw mus rau lwm qhov. Siv nyob rau hauv kev sib kis kab mob, nws hloov lub zog los ntawm ib qho chaw xws li lub cav mus rau ntau yam khoom xws li lub log. Yog li, cov khoom lag luam kuj tau siv dav hauv kev lag luam xws li kev tsim tshuab, khoom siv ua liaj ua teb, tsheb, thiab khoom siv tub rog.
Novel Kev txhawj xeeb
Retatrutide qhia txog ob qhov kev xav txog kev nyab xeeb tshwj xeeb:
Paresthesia: 20.9% ntawm cov neeg mob hauv pawg 12 mg tau tshaj tawm qhov txawv txav ntawm kev hnov qab (xws li, tingling, loog loog), tej zaum yuav txuas rau GCGR- kho qhov nruab nrab ntawm lub paj hlwb. Tus nqi no siab dua tirzepatide (8.9%) tab sis tsis tshua muaj kev cuam tshuam rau kev txiav.
Kev pheej hmoo ntawm hypoglycemia: Txawm hais tias GCGR ua kom muaj zog, mob ntshav qab zib ntau heev (cov ntshav qabzib<54 mg/dL) occurred in 0.5% of participants, primarily those on concomitant sulfonylureas or insulin.
Discontinuation Rate
Kwv yees li ntawm 18% ntawm cov neeg koom nrog thim rov qab los ntawm qhov kev sim siab vim muaj cov xwm txheej tsis zoo, nrog cov qib siab dua hauv 12 mg pawg (22%) piv rau 9 mg (15%) thiab placebo (5%). Qhov tseem ceeb, 7% ntawm kev txiav tawm hauv pawg tshuaj ntau tshaj plaws yog vim "qhov hnyav dhau lawm," qhia txog qhov kev sib tw tshiab hauv kev kho mob rog rog.
Kev taw qhia yav tom ntej
Pending Theem 3 Kev sim:
Lilly npaj yuav nthuav tawm cov txiaj ntsig los ntawm xya qhov kev sim Phase 3 ntxiv los ntawm 2026, tshawb txog Retatrutide qhov ua tau zoo hauv:
Tsis yog -alcoholic steatohepatitis (NASH): Ib 72-lub lim tiam sim (NCT05594706) lub hom phiaj los ua kom pom cov kev daws teeb meem ntawm daim siab fibrosis.
Obstructive pw tsaug zog apnea (OSA): A 52- txoj kev tshawb fawb lub lim tiam (NCT05699956) yuav ntsuas qhov txo qis hauv apnea-hypopnea index (AHI) thiab cov xwm txheej oxygen desaturation.
Kev mob qis qis: Kev sim 48 lub lis piam (NCT05701012) yuav ntsuas qhov mob hnyav thiab kev txhim kho kev ua haujlwm ntawm Oswestry Disability Index.
Kev sib xyaw ua ke:
Retatrutide's mechanism ua tiav lwm cov tshuaj metabolic, qhib txoj hauv kev rau kev sib xyaw ua ke:
SGLT2 inhibitors: Ua ke nrog empagliflozin tuaj yeem txhim kho lub raum kev tiv thaiv thiab tswj glycemic hauv T2DM.
FXR agonists: Co- kev tswj hwm nrog obeticholic acid tuaj yeem ua kom NASH daws teeb meem los ntawm kev tsom mus rau cov kua qaub kua qaub thiab o.
Amylin analogs: Kev sib xyaw nrog pramlintide tuaj yeem txo qis qab los noj mov thiab txo qis glucagon secretion postprandial.
Tom ntej no -Tsim Cov Qauv:
Txhawm rau txhim kho kev nkag mus tau zoo, Lilly tab tom tsim:
Qhov ncauj Retatrutide: Siv permeation enhancers thiab enzyme inhibitors, Phase 1 sim qhia 12% bioavailability, piv rau qhov ncauj semaglutide.
Microneedle thaj ua rau thaj: Soluble polymer microarrays pab kom tsis txhob mob txhua lub lim tiam, nrog cov ntaub ntawv preclinical txuam nrog kev txhaj tshuaj zoo.
Retatrutide's triple-agonism sawv cev rau quantum leap hauv kev kho cov kab mob metabolic, muab cov txiaj ntsig zoo tsis sib xws ntawm kev poob phaus, tswj glycemic, thiab tswj kev sib txuam. Thaum lub plab hnyuv siab raum thiab ntev - lub sijhawm kev nyab xeeb tseem nyob rau thaj chaw rau kev kho kom zoo, nws cov ntaub ntawv kho mob tso nws ua lub hauv paus tseem ceeb ntawm kev rog rog thiab kev kho T2DM. Raws li Eli Lilly nthuav tawm nws cov ntaub ntawv qhia txog kev sib tw thiab cov neeg sib tw ua kom muaj kev sib tw, kev sib tw los tswj hwm $ 200 billion metabolic therapeutics kev lag luam yuav cuam tshuam rau kev tsim kho tshiab, kev nkag mus tau, thiab tus neeg mob- kev saib xyuas zoo. Retatrutide txoj kev taug-los ntawm kev kuaj ntsuas mus rau thoob ntiaj teb tus qauv ntawm kev saib xyuas-embodies cov lus cog tseg ntawm cov tshuaj muaj tseeb hauv kev daws ib qho ntawm tib neeg cov teeb meem kev noj qab haus huv tseem ceeb tshaj plaws.